@prefix rdf:	<http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix ns1:	<http://linked.opendata.cz/resource/drugbank/drug/> .
@prefix ns2:	<http://linked.opendata.cz/ontology/drugbank/> .
ns1:DB00981	rdf:type	ns2:Drug ;
	ns2:description	"A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. [PubChem]"@en ;
	ns2:group	"approved"@en ;
	ns2:indication	"For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity."@en .
@prefix owl:	<http://www.w3.org/2002/07/owl#> .
@prefix ns4:	<http://bio2rdf.org/drugbank:> .
ns1:DB00981	owl:sameAs	ns4:DB00981 .
@prefix ns5:	<http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/> .
ns1:DB00981	owl:sameAs	ns5:DB00981 .
@prefix dcterms:	<http://purl.org/dc/terms/> .
ns1:DB00981	dcterms:title	"Physostigmine"@en .
@prefix adms:	<http://www.w3.org/ns/adms#> .
ns1:DB00981	adms:identifier	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/pubchem-substance/46506998> .
@prefix ns8:	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/pharmgkb/> .
ns1:DB00981	adms:identifier	ns8:PA450957 ,
		<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/pubchem-compound/5983> .
@prefix ns9:	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/kegg-compound/> .
ns1:DB00981	adms:identifier	ns9:C06535 .
@prefix ns10:	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/kegg-drug/> .
ns1:DB00981	adms:identifier	ns10:D00196 .
@prefix ns11:	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/drugbank/> .
ns1:DB00981	adms:identifier	ns11:DB00981 ,
		<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/chebi/27953> ,
		<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/chemspider/5763> .
@prefix ns12:	<http://linked.opendata.cz/resource/drugbank/drug/DB00981/identifier/wikipedia/> .
ns1:DB00981	adms:identifier	ns12:Physostigmine ;
	ns2:mechanismOfAction	"Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse."@en ;
	ns2:packager	<http://linked.opendata.cz/resource/drugbank/company/271B489F-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B48A0-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B489D-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B489E-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B48A1-363D-11E5-9242-09173F13E4C5> ;
	ns2:synonym	"Antilirium"@en ,
		"Physostigmine"@en ,
		"Physostol"@en ,
		"Eserine"@en ;
	ns2:toxicity	"Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain."@en ;
	ns2:salt	"       "@en ;
	ns2:synthesisReference	"Edward J. Glamkowski, Barbara E. Kurys, \"4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof.\" U.S. Patent US5081117, issued September, 1978."@en .
@prefix ns13:	<http://linked.opendata.cz/ontology/mesh/> .
@prefix ns14:	<http://linked.opendata.cz/resource/mesh/concept/> .
ns1:DB00981	ns13:hasConcept	ns14:M0016815 .
@prefix foaf:	<http://xmlns.com/foaf/0.1/> .
ns1:DB00981	foaf:page	<http://www.rxlist.com/cgi/generic/physostigmine.htm> ,
		<http://www.drugs.com/mtm/physostigmine-ophthalmic.html> ;
	ns2:IUPAC-Name	<http://linked.opendata.cz/resource/drugbank/property/271B48A8-363D-11E5-9242-09173F13E4C5> ;
	ns2:InChI	<http://linked.opendata.cz/resource/drugbank/property/271B48AE-363D-11E5-9242-09173F13E4C5> ;
	ns2:Molecular-Formula	<http://linked.opendata.cz/resource/drugbank/property/271B48AD-363D-11E5-9242-09173F13E4C5> ;
	ns2:Molecular-Weight	<http://linked.opendata.cz/resource/drugbank/property/271B48AA-363D-11E5-9242-09173F13E4C5> ;
	ns2:Monoisotopic-Weight	<http://linked.opendata.cz/resource/drugbank/property/271B48AB-363D-11E5-9242-09173F13E4C5> ;
	ns2:SMILES	<http://linked.opendata.cz/resource/drugbank/property/271B48AC-363D-11E5-9242-09173F13E4C5> ;
	ns2:Water-Solubility	<http://linked.opendata.cz/resource/drugbank/property/271B48A6-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/property/271B48BE-363D-11E5-9242-09173F13E4C5> ;
	ns2:logP	<http://linked.opendata.cz/resource/drugbank/property/271B48A7-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/property/271B48A4-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/property/271B48C0-363D-11E5-9242-09173F13E4C5> ;
	ns2:logS	<http://linked.opendata.cz/resource/drugbank/property/271B48A5-363D-11E5-9242-09173F13E4C5> ;
	ns2:pKa	<http://linked.opendata.cz/resource/drugbank/property/271B48C1-363D-11E5-9242-09173F13E4C5> .
@prefix ns16:	<http://linked.opendata.cz/ontology/sukl/drug/> .
@prefix ns17:	<http://linked.opendata.cz/resource/atc/> .
ns1:DB00981	ns16:hasATCCode	ns17:V03AB19 ,
		ns17:S01EB05 ;
	ns2:H-Bond-Acceptor-Count	<http://linked.opendata.cz/resource/drugbank/property/271B48B4-363D-11E5-9242-09173F13E4C5> ;
	ns2:H-Bond-Donor-Count	<http://linked.opendata.cz/resource/drugbank/property/271B48B5-363D-11E5-9242-09173F13E4C5> ;
	ns2:InChIKey	<http://linked.opendata.cz/resource/drugbank/property/271B48AF-363D-11E5-9242-09173F13E4C5> ;
	ns2:Polar-Surface-Area--PSA-	<http://linked.opendata.cz/resource/drugbank/property/271B48B0-363D-11E5-9242-09173F13E4C5> ;
	ns2:Polarizability	<http://linked.opendata.cz/resource/drugbank/property/271B48B2-363D-11E5-9242-09173F13E4C5> ;
	ns2:Refractivity	<http://linked.opendata.cz/resource/drugbank/property/271B48B1-363D-11E5-9242-09173F13E4C5> ;
	ns2:Rotatable-Bond-Count	<http://linked.opendata.cz/resource/drugbank/property/271B48B3-363D-11E5-9242-09173F13E4C5> ;
	ns2:affectedOrganism	"Humans and other mammals"@en ;
	ns2:casRegistryNumber	"57-47-6"@en ;
	ns2:category	"       "@en ;
	ns2:containedIn	<http://linked.opendata.cz/resource/drugbank/medicinal-product/271B48A3-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/medicinal-product/271B48A2-363D-11E5-9242-09173F13E4C5> ;
	ns2:Bioavailability	<http://linked.opendata.cz/resource/drugbank/property/271B48BA-363D-11E5-9242-09173F13E4C5> ;
	ns2:Ghose-Filter	<http://linked.opendata.cz/resource/drugbank/property/271B48BC-363D-11E5-9242-09173F13E4C5> ;
	ns2:MDDR-Like-Rule	<http://linked.opendata.cz/resource/drugbank/property/271B48BD-363D-11E5-9242-09173F13E4C5> ;
	ns2:Melting-Point	<http://linked.opendata.cz/resource/drugbank/property/271B48BF-363D-11E5-9242-09173F13E4C5> ;
	ns2:Number-of-Rings	<http://linked.opendata.cz/resource/drugbank/property/271B48B9-363D-11E5-9242-09173F13E4C5> ;
	ns2:Physiological-Charge	<http://linked.opendata.cz/resource/drugbank/property/271B48B8-363D-11E5-9242-09173F13E4C5> ;
	ns2:Rule-of-Five	<http://linked.opendata.cz/resource/drugbank/property/271B48BB-363D-11E5-9242-09173F13E4C5> ;
	ns2:Traditional-IUPAC-Name	<http://linked.opendata.cz/resource/drugbank/property/271B48A9-363D-11E5-9242-09173F13E4C5> ;
	ns2:pKa--strongest-acidic-	<http://linked.opendata.cz/resource/drugbank/property/271B48B6-363D-11E5-9242-09173F13E4C5> ;
	ns2:pKa--strongest-basic-	<http://linked.opendata.cz/resource/drugbank/property/271B48B7-363D-11E5-9242-09173F13E4C5> .